– Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform –
WIRE) –February 5, 2020– Immusoft Corporation, a Seattle-Wash.-based,
leading cell therapy company, today announced that Scott McIvor, Ph.D., Chief
Development Officer, and Professor Genetics, Cell Biology, and Development at
the University of Minnesota, will present at the 16th Annual WorldSymposium™,
hosted in Orlando, FL, February 10-13, 2020. WorldSymposium™ is the
largest international gathering of lysosomal disease researchers.
Dr. McIvor will present, “Iduronidase-transposed
human B lymphocytes correct enzyme deficiency and glycosaminoglycan storage
disease in immunodeficient MPS I mice,” during the Contemporary Forum session
at 4:15 p.m. ET / 1:15 p.m. PT on Thursday, February 13, 2020.
With over 150 publications, Dr. McIvor is one of
the earliest pioneers in gene transfer and gene therapy. Dr. McIvor received
his Ph.D. in Microbiology from the University of Minnesota in 1982. He
completed his postdoctoral work at the University of California, San Francisco,
and then at Genentech, Inc., where he conducted early work on therapeutic gene
transfer into mouse hematopoietic stem cells using retroviral vectors. Dr.
McIvor has been on the faculty at the University of Minnesota since 1986, where
he has worked on the development of genetic therapies for cancer and inherited
metabolic and immunodeficiency diseases using viral and non-viral vector
systems. Starting in 2006, Dr. McIvor was CEO and Chief Science Officer of
Discovery Genomics, Inc. (DGI), founded in part to develop the Sleeping Beauty
transposon system. In 2016, DGI was acquired by Immusoft Corporation where Dr.
McIvor currently serves as Chief Development Officer. Dr. McIvor also served on
the NIH Recombinant DNA Advisory Committee and is an industry-recognized key
thought leader for lysosomal storage disorders.
Additional information regarding the ISP™ platform
and the WORLDSymposium™ presentation can be found at: https://immusoft.com/technology/.
About Immune System Programming (ISP™) Technology
Immusoft’s proprietary ISP™
platform technology is a gene modified cell therapy approach that uses a
clinically validated, non-viral vector that aims to safely and reliably insert
functional genes into immune cells. Once administered back into the patient, a
subset of ISP™ modified cells are expected to reside within survival niches in
the body, continuously producing gene-encoded protein(s). The platform’s broad
utility to produce a wide range of therapeutic protein classes (e.g.
antibodies, signaling proteins, and enzymes), has the potential to disrupt the
current standard of care for many diseases requiring protein injections or
infusions, including many to address orphan diseases.
About Mucopolysaccharidosis type I (MPS I)
MPS I is a rare, lethal childhood
genetic disease that affects the body’s ability to produce IDUA
(alpha-L-iduronidase), which is an essential enzyme that helps to break down
long-chain sugars inside cells. When the sugar chains cannot be broken down and
disposed of, they accumulate in the cells and cause progressive damage. In its
most severe form, and if left untreated, children affected rarely live longer
than ten years after diagnosis.
(immusoft.com) mission is to treat diseases using its breakthrough technology
platform called Immune System Programming (ISP™). The technology modifies a
patient’s B cells and instructs the cells to produce gene-encoded medicines
(biologics). The B cells that are reprogrammed using ISP become miniature drug
factories that are expected to survive in patients for many years. Immusoft
Corporation is based in Seattle, Washington.
Media & Investors
Glenn Schulman, PharmD, MPH
Z3 Biocommunications, LLC
SAN FRANCISCO–(BUSINESS WIRE)– Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support the development of its ISP- 002 (for delivery of iduronate sulfatase) program in mucopolysaccharidosis type II (MPS II), an inherited disease for which patients have limited options.